The synthesis and SAR studies of a novel N-aryl pyridinone class of p38 kinase inhibitors are described. Systematic structural modifications to the HTS lead, 5, led to the identification of (-)-4a as a clinical candidate for the treatment of inflammatory diseases. Additionally, the chiral synthesis and properties of (-)-4a are described.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2011.04.121 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!